Oncotelic Therapeutics, Inc.
OTLC
$0.0501
-$0.0032-6.00%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -34.82% | 208.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -34.72% | 220.95% | |||
| Operating Income | 34.72% | -220.95% | |||
| Income Before Tax | 157.75% | 44.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 157.75% | 44.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 2.90% | 22.43% | |||
| Net Income | 193.04% | 50.29% | |||
| EBIT | 34.72% | -220.95% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 200.00% | 53.33% | |||
| Normalized Basic EPS | 225.00% | 55.56% | |||
| EPS Diluted | 185.71% | 53.33% | |||
| Normalized Diluted EPS | 200.00% | 55.56% | |||
| Average Basic Shares Outstanding | 0.21% | 0.03% | |||
| Average Diluted Shares Outstanding | 11.14% | 0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||